Name: patient-derived tumor explants as a "live" preclinical platform for predicting drug resistance in patients
Uploaded: 2021-02-07T14:30:00.000+00:00
Duration: 7 min 42 s
Description: Watch this Scientific Journal Video about Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients at JoVE.com

We thank the surgeons and pathologists at University Hospitals of Leicester NHS Trust for providing surgical resected tumor tissue. We also thank the Histology facility within Core Biotechnology Services for help with tissue processing and sectioning of FFPE tissue blocks and Kees Straatman for support with use of the Vectra Polaris. This research was supported and funded by the Explant Consortium comprising four partners: The University of Leicester, The MRC Toxicology Unit, Cancer Research UK Therapeutic Discovery Laboratories, and LifeArc. Additional support was provided by the CRUK-NIHR Leicester Experimental Cancer Medicine Centre (C10604/A25151). Funding for GM, CD, and NA was provided by Breast Cancer Now&#39;s Catalyst Programme (2017NOVPCC1066), which is supported by funding from Pfizer.

Nothing to disclose

This paper describes the methods for generation, drug treatment, and analysis of PDEs and highlights the advantages of the platform as a preclinical model system. Ex vivo&#160;culturing of a freshly resected tumor, which does not involve its deconstruction, allows for the retention of the tumor architecture13,24 and thus, the spatial interactions of cellular components in the TME as well as intratumoral heterogeneity. This method demonstrates how, by using a tumo...

The development of effective and safe anticancer agents requires appropriate preclinical models that can also provide insight into mechanisms of action that can facilitate the identification of predictive and pharmacodynamic biomarkers. Inter- and intratumor heterogeneity1,2,3,4,5 and the TME6,7,8,9,10,11,12 are known to influence anticancer drug responses, and many existing preclinical cancer models such as cell lines, organoids, and mouse models are not able to fully accommodate these crucial features. An &#34;ideal&#34; model is one that can recapitulate the complex spatial interactions of malignant with non-malignant cells within tumors as well as reflect the regional differences within tumors. This article focuses on PDEs as an emerging platform that can fulfil many of these requirements13.
The first example of the use of human PDEs, also known as histocultures, dates back to the late 1980s when Hoffman et al. generated slices of freshly resected human tumors and cultured them in a collagen matrix14,15. This involved establishing a 3D culture system that preserved tissue architecture, ensuring the maintenance of stromal components and cell interactions within the TME. Without deconstructing the original tumor, Hoffman et al.16 heralded a new approach of translational research, and since this time, many groups have optimized different explant methods with the aim of preserving the tissue integrity and generating accurate drug response data17,18,19,20,21,22,23,24, although some differences between protocols are evident. Butler et al. cultured explants in gelatin sponges to help the diffusion of nutrients and drugs through the specimen20,21,25, whereas Majumder et al. created a tumor ecosystem by culturing explants on top of a matrix composed of tumor and stromal proteins in the presence of autologous serum derived from the same patient22,23.
More recently, our group set up a protocol whereby explants are generated by fragmentation of tumors into 2 - 3 mm3-sized pieces that are then placed without additional components on permeable membranes at the air-liquid interface of a culture system24. Taken together,&#160;these numerous studies have demonstrated that PDEs allow the culture of intact, live fragments of human tumors that retain the spatial architecture and regional heterogeneity of the original tumors. In original experiments, explants or histocultures were usually subjected to homogenization following drug treatment, after which various viability assays were applied to the homogenized samples such as the histoculture drug response assay20,21, the MTT (3-(6)-2,5-diphenyltetrazolium bromide) assay, the lactate dehydrogenase assay, or the resazurin-based assay26,27,28. Recent progress in endpoint analysis techniques, particularly digital pathology, have now expanded the repertoire of endpoint tests and assays that can be performed on explants29,30. To apply these new technologies, instead of homogenization, explants are fixed in formalin, embedded in paraffin (FFPE) and then analyzed using immunostaining techniques, allowing spatial profiling. Examples of this approach have been documented for non-small cell lung cancer (NSCLC), breast cancer, colorectal cancer, and mesothelioma explants whereby immunohistochemical staining for the proliferation marker, Ki67, and the apoptotic marker, cleaved poly-ADP ribose polymerase (cPARP), was used to monitor changes in cell proliferation and cell death24,31,32,33,34.
Multiplexed immunofluorescence is particularly amenable for spatial profiling of drug responses in explants at endpoint35. For example, it is possible to measure the relocalization and spatial distribution of specific classes of immune cells, such as macrophages or T cells, within the TME upon drug treatment13,36,37,38, and investigate whether a therapeutic agent can favor the transition from &#34;cold tumor&#34; to &#34;hot tumor&#34;39. In recent years, this group has focused on the derivation of PDEs from different tumor types (NSCLC, renal cancer, breast cancer, colorectal cancer, melanoma) and the testing of a range of anticancer agents including chemotherapies, small-molecule inhibitors, and immune checkpoint inhibitors (ICIs). Endpoint analysis methods have been optimized to include multiplexed immunofluorescence to allow spatial profiling of biomarkers for viability as well as biomarkers for different constituents of the TME.

<table><tbody><tr><td>&lt;strong&gt;Acetic acid&lt;/strong&gt;</td><td>Sigma</td><td>320099</td><td>Staining reagent</td></tr><tr><td>&lt;strong&gt;Antibody Diluent / Block, 1x&lt;/strong&gt;</td><td>Perkin Elmer</td><td>ARD1001EA</td><td>Antibody diluent/blocking buffer</td></tr><tr><td>&lt;strong&gt;Barnstead NANOpure Diamond&lt;/strong&gt;</td><td>Barnstead</td><td></td><td>Ultra Pure (UP) H&lt;sub&gt;2&lt;/sub&gt;O machine</td></tr><tr><td>&lt;strong&gt;Citric Acid Monohydrate&lt;/strong&gt;</td><td>Sigma-Aldrich</td><td>C7129</td><td>Reagent for citrate buffer</td></tr><tr><td>&lt;strong&gt;Costar Multiple Well Cell Culture Plates&lt;/strong&gt;</td><td>Corning Incorporated</td><td>3516</td><td>6 multiwell plate</td></tr><tr><td>&lt;strong&gt;DAPI Dilactate&lt;/strong&gt;</td><td>Life Technologies</td><td>D3571</td><td></td></tr><tr><td>&lt;strong&gt;100 x 17 mm Dish, Nunclon Delta&lt;/strong&gt;</td><td>ThermoFisher Scientific</td><td>150350</td><td>100 mm diameter dish for tissue culture</td></tr><tr><td>&lt;strong&gt;DMEM (1x) Dubelcco&#039;s Modified Eagle Medium + 4.5 g/L D-Glucose + 110 mg/mL Sodium Pyruvate&lt;/strong&gt;</td><td>Gibco (Life Technologies)</td><td>10569-010</td><td>Tissue culture medium (500 mL)</td></tr><tr><td>&lt;strong&gt;DPX mountant&lt;/strong&gt;</td><td>VWR</td><td>360294H</td><td>Mounting medium</td></tr><tr><td>&lt;strong&gt;DPX mountant&lt;/strong&gt;</td><td>Merck</td><td>6522</td><td>Mounting medium</td></tr><tr><td>&lt;strong&gt;Ethylenediaminetetraacetic acid (EDTA)&lt;/strong&gt;</td><td>Sigma-Aldrich</td><td>3609</td><td>Reagent for TE buffer</td></tr><tr><td>&lt;strong&gt;Eosin&lt;/strong&gt;</td><td>CellPath</td><td>RBC-0100-00A</td><td>Staining reagent</td></tr><tr><td>&lt;strong&gt;Foetal Bovine Serum&lt;/strong&gt;</td><td>Gibco</td><td>10500-064</td><td>For use in tissue culture medium</td></tr><tr><td>&lt;strong&gt;37% Formaldehyde&lt;/strong&gt;</td><td>Fisher (Acros)</td><td>119690010</td><td>10% Formalin</td></tr><tr><td>&lt;strong&gt;iGenix, microwave oven IG2095&lt;/strong&gt;</td><td>iGenix</td><td>IG2095</td><td>Microwave used for antigen retreival</td></tr><tr><td>&lt;strong&gt;Industrial methylated spirit (IMS)&lt;/strong&gt;</td><td>Genta Medical</td><td>199050</td><td>99% Industrial Denatured Alcohol (IDA)</td></tr><tr><td>&lt;strong&gt;InForm Advanced Image Analysis Software&lt;/strong&gt;</td><td>Akoya Biosciences</td><td>InForm</td><td></td></tr><tr><td>&lt;strong&gt;Leica ASP3000 Tissue Processor&lt;/strong&gt;</td><td>Leica Biosystems</td><td></td><td>Automated Vacuum Tissue Processor</td></tr><tr><td>&lt;strong&gt;Leica Arcadia H and C&lt;/strong&gt;</td><td>Leica Biosystems</td><td></td><td>Embedding wax bath</td></tr><tr><td>&lt;strong&gt;Leica RM2125RT&lt;/strong&gt;</td><td>Leica Biosystems</td><td></td><td>Rotary microtome</td></tr><tr><td>&lt;strong&gt;Leica ST4040 Linear Stainer&lt;/strong&gt;</td><td>Leica Biosystems</td><td></td><td>H&amp;amp;E stainer</td></tr><tr><td>&lt;strong&gt;Mayer&#039;s Haematoxylin&lt;/strong&gt;</td><td>Sigma</td><td>GHS132-1L</td><td>Staining reagent</td></tr><tr><td>&lt;strong&gt;Millicell Cell Culture Inserts, 30 mm, hydrophilic PTFE, 0.4 &amp;micro;m&lt;/strong&gt;</td><td>Merck Milipore</td><td>PICMORG50</td><td>Organotypic culture insert disc</td></tr><tr><td>&lt;strong&gt;Novolink Polymer Detection System&lt;/strong&gt;</td><td>Leica Biosystems</td><td>RE7150-K</td><td>DAB staining kit</td></tr><tr><td>&lt;strong&gt;OPAL 480&lt;/strong&gt;</td><td>Akoya Biosciences</td><td>FP1500001KT</td><td>Fluorophore with Dimethyl Sulfoxide (DMSO) diluent</td></tr><tr><td>&lt;strong&gt;OPAL 520&lt;/strong&gt;</td><td>Akoya Biosciences</td><td>FP1487001KT</td><td>Fluorophore with Dimethyl Sulfoxide (DMSO) diluent</td></tr><tr><td>&lt;strong&gt;OPAL 570&lt;/strong&gt;</td><td>Akoya Biosciences</td><td>FP1488001KT</td><td>Fluorophore with Dimethyl Sulfoxide (DMSO) diluent</td></tr><tr><td>&lt;strong&gt;OPAL 620&lt;/strong&gt;</td><td>Akoya Biosciences</td><td>FP1495001KT</td><td>Fluorophore with Dimethyl Sulfoxide (DMSO) diluent</td></tr><tr><td>&lt;strong&gt;OPAL 650&lt;/strong&gt;</td><td>Akoya Biosciences</td><td>FP1496001KT</td><td>Fluorophore with Dimethyl Sulfoxide (DMSO) diluent</td></tr><tr><td>&lt;strong&gt;OPAL 690&lt;/strong&gt;</td><td>Akoya Biosciences</td><td>FP1497001KT</td><td>Fluorophore with Dimethyl Sulfoxide (DMSO) diluent</td></tr><tr><td>&lt;strong&gt;OPAL 780 / OPAL TSA-DIG Reagent&lt;/strong&gt;</td><td>Akoya Biosciences</td><td>FP1501001KT</td><td>Fluorophore with Dimethyl Sulfoxide (DMSO) diluent and TSA-DIG reagent</td></tr><tr><td>&lt;strong&gt;Opal Polymer HRP Ms Plus Rb, 1x&lt;/strong&gt;</td><td>Perkin Elmer</td><td>ARH1001EA</td><td>HRP polymer</td></tr><tr><td>&lt;strong&gt;Penicillin/streptomycin solution&lt;/strong&gt;</td><td>Fisher Scientific</td><td>11548876</td><td>For use in tissue culture medium</td></tr><tr><td>&lt;strong&gt;PhenoChart Whole Slide Contextual Viewer&lt;/strong&gt;</td><td>Akoya Biosciences</td><td>PhenoChart</td><td>Viewer software for scanned images</td></tr><tr><td>&lt;strong&gt;Phosphate Buffered Saline Tablets&lt;/strong&gt;</td><td>Thermo Scientific Oxoid</td><td>BR0014G</td><td>PBS</td></tr><tr><td>&lt;strong&gt;1x Plus Amplification Diluent&lt;/strong&gt;</td><td>Perkin Elmer</td><td>FP1498</td><td>Fluorophore diluent</td></tr><tr><td>&lt;strong&gt;Prolong Diamond Antifade Mountant&lt;/strong&gt;</td><td>Invitrogen</td><td>P36961</td><td>Mounting medium</td></tr><tr><td>&lt;strong&gt;Slide Carrier&lt;/strong&gt;</td><td>Perkin Elmer</td><td></td><td>To load slides into Slide Carrier Hotel for scanning with Vectra Polaris</td></tr><tr><td>&lt;strong&gt;Sodium Chloride&lt;/strong&gt;</td><td>Fisher Scientific</td><td>S/3160/63</td><td>10% Formalin</td></tr><tr><td>&lt;strong&gt;Sodium Hydroxide pellets&lt;/strong&gt;</td><td>Fisher Scientific</td><td>S/4920/53</td><td>Reagent for citrate buffer</td></tr><tr><td>&lt;strong&gt;Tenatex Toughened Wax - Pink (500 g)&lt;/strong&gt;</td><td>KEMDENT</td><td>1-601</td><td>Dental wax surface</td></tr><tr><td>&lt;strong&gt;Thermo Scientific&amp;nbsp;Shandon Sequenza Slide Rack for Immunostaining Center&lt;/strong&gt;</td><td>Fisher Scientific</td><td>10098889</td><td>Holder for slides and slide clips</td></tr><tr><td>&lt;strong&gt;Thermo Scientific Shandon Plastic Coverplates&lt;/strong&gt;</td><td>Fisher Scientific</td><td>11927774</td><td>Slide clips</td></tr><tr><td>&lt;strong&gt;Tris(hydroxymethyl)aminomethane (Tris)&lt;/strong&gt;</td><td>Sigma-Aldrich</td><td>252859</td><td>Reagent for TE buffer</td></tr><tr><td>&lt;strong&gt;VectaShield&lt;/strong&gt;</td><td>Vecta Laboratories</td><td>H-1000-10</td><td>Mounting medium</td></tr><tr><td>&lt;strong&gt;Vectra Polaris Slide Scanner&lt;/strong&gt;</td><td>Perkin Elmer</td><td>Vectra Polaris</td><td>Slide scanner</td></tr><tr><td>&lt;strong&gt;Xylene&lt;/strong&gt;</td><td>Genta Medical</td><td>XYL050</td><td>De-waxing agent</td></tr></tbody></table>

patient-derived tumor explants as a "live" preclinical platform for predicting drug resistance in patients

An understanding of drug resistance and the development of novel strategies to sensitize highly resistant cancers rely on the availability of suitable preclinical models that can accurately predict patient responses. One of the disadvantages of existing preclinical models is the inability to contextually preserve the human tumor microenvironment (TME) and accurately represent intratumoral heterogeneity, thus limiting the clinical translation of data. By contrast, by representing the culture of live fragments of human tumors, the patient-derived explant (PDE) platform allows drug responses to be examined in a three-dimensional (3D) context that mirrors the pathological and architectural features of the original tumors as closely as possible. Previous reports with PDEs have documented the ability of the platform to distinguish chemosensitive from chemoresistant tumors, and it has been shown that this segregation is predictive of patient responses to the same chemotherapies. Simultaneously, PDEs allow the opportunity to interrogate molecular, genetic, and histological features of tumors that predict drug responses, thereby identifying biomarkers for patient stratification as well as novel interventional approaches to sensitize resistant tumors. This paper reports PDE methodology in detail, from collection of patient samples through to endpoint analysis. It provides a detailed description of explant derivation and culture methods, highlighting bespoke conditions for particular tumors, where appropriate. For endpoint analysis, there is a focus on multiplexed immunofluorescence and multispectral imaging for the spatial profiling of key biomarkers within both tumoral and stromal regions. By combining these methods, it is possible to generate quantitative and qualitative drug response data that can be related to various clinicopathological parameters and thus potentially be used for biomarker identification.

Multispectral imaging of mIF-stained histological sections permits identification and phenotyping of individual cell populations and identification of tumor and stromal components in the explant TME (Figure 2). Multispectral imaging is particularly useful for the analysis of tissues with high intrinsic autofluorescence, such as tissue with a high collagen content, as it allows the autofluorescence signal to be deconvoluted from other signals and excluded from subsequent analysis. Subsequent ...

Watch this Scientific Journal Video about Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients at JoVE.com

Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients

This paper describes methods for the generation, drug treatment, and analysis of patient-derived explants for assessing tumor drug responses in a live, patient-relevant, preclinical model system.

An understanding of drug resistance and the development of novel strategies to sensitize highly resistant cancers rely on the availability of suitable ...

patient-derived-tumor-explants-as-live-preclinical-platform-for

Research

JoVE Journal

Cancer Research

4.8K Views.  University of Leicester. This paper describes methods for the generation, drug treatment, and analysis of patient-derived explants for assessing tumor drug responses in a live, patient-relevant, preclinical model system.

Video: Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies

Patient derived tumor xenograft (PDTX) models provide a necessary platform in facilitating anti-cancer drug development prior to human trials. Human tumor pieces are injected subcutaneously into athymic nude mice (immunocompromised, T cell deficient) to create a bank of tumors and subsequently are passaged into different generations of mice in order to maintain these tumors from patients. Importantly, cellular heterogeneity of the original tumor is closely emulated in this model, which provides a more clinically relevant model for evaluation of drug efficacy studies (single agent and combination), biomarker analysis, resistant pathways and cancer stem cell biology. Some limitations of the PDTX model include the replacement of the human stroma with mouse stroma after the first generation in mice, inability to investigate treatment effects on metastasis due to the subcutaneous injections of the tumors, and the lack of evaluation of immunotherapies due to the use of immunocompromised mice. However, even with these limitations, the PDTX model provides a powerful preclinical platform in the drug discovery process.

Utilizing patient-derived tumors in a subcutaneous preclinical model is an excellent way to study the efficacy of novel therapies, predictive biomarker discovery, and drug resistant pathways. This model, in the drug development process, is essential in determining the fate of many novel anti-cancer therapies prior to clinical investigation.

Patient derived tumor xenograft (PDTX) models provide a necessary platform in facilitating anti-cancer drug development prior to human trials. Human tumor ...

Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel

Microtubule targeting agents (MTAs) are a mainstay in the treatment of a wide range of tumors. However, acquired resistance to chemotherapeutic drugs is a common mechanism of disease progression and a prognostic-determinant feature of malignant tumors. In prostate cancer (PC), resistance to MTAs such as the taxane Docetaxel dictates treatment failure as well as progression towards lethal stages of disease that are defined by a poor prognosis and high mortality rates. Though studied for decades, the array of mechanisms contributing to acquired resistance are not completely understood, and thus pose a significant limitation to the development of new therapeutic strategies that could benefit patients in these advanced stages of disease. In this protocol, we describe the generation of Docetaxel-resistant prostate cancer cell lines that mimic lethal features of late-stage prostate cancer, and therefore can be used to study the mechanisms by which acquired chemoresistance arises. Despite potential limitations intrinsic to a cell based model, such as the loss of resistance properties over time, the Docetaxel-resistant cell lines produced by this method have been successfully used in recent studies and offer&#160;the opportunity to advance our molecular understanding of acquired chemoresistance in lethal prostate cancer.

Resistance to cancer therapies contributes to disease progression and death. Determining the mechanistic underpinnings of resistance is crucial for improving therapeutic response. This manuscript details the protocol to generate taxane-resistant cell models of prostate cancer (PC) to help dissecting the pathways involved in progression to Docetaxel resistance in PC patients.

Microtubule targeting agents (MTAs) are a mainstay in the treatment of a wide range of tumors. However, acquired resistance to chemotherapeutic drugs is a ...

Method for Novel Anti-Cancer Drug Development using Tumor Explants of Surgical Specimens

The current therapies for malignant glioma have only palliative effect. For therapeutic development, one hurdle is the discrepancy of efficacy determined by current drug efficacy tests and the efficacy on patients. Thus, novel and reliable methods for evaluating drug efficacy are warranted in pre-clinical phase. In vitro culture of tumor tissues, including cell lines, has substantial phenotypic, genetic, and epigenetic alterations of cancer cells caused by artificial environment of cell culture, which may not reflect the biology of original tumors in situ. Xenograft models with the immunodeficient mice also have limitations, i.e., the lack of immune system and interspecies genetic and epigenetic discrepancies in microenvironment. Here, we demonstrate a novel method using the surgical specimens of malignant glioma as undissociated tumor blocks to evaluate treatment effects. To validate this method, data with the current first-line chemotherapeutic agent, temozolomide (TMZ), are described.


We used the freshly-removed surgical specimen of malignant glioma for our experiments. We performed intratumoral injection of TMZ or other drug candidates, followed by incubation and analysis on surgical specimens. Here, we sought to establish a tumor tissue explant method as a platform to determine the efficacy of novel anti-cancer therapies so that we may be able to overcome, at least, some of the current limitations and fill the existing gap between the current experimental data and the efficacy on an actual patient's tumor. This method may have the potential to accelerate identifying novel chemotherapeutic agents for solid cancer treatment.

Here, we established a method for drug efficacy testing with surgical specimens of brain tumors, termed &#x201C;tumor explant method&#x201D;. With this method, we can evaluate drug efficacy without breaking the microenvironment of solid tumors. To validate reliability of this method, we describe representative data with our glioma specimen treated with the current first-line chemotherapeutic agent, temozolomide.


The current therapies for malignant glioma have only palliative effect. For therapeutic development, one hurdle is the discrepancy of efficacy determined ...

Medicine

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

We present here an integrative approach for testing efficacy of targeted therapies that combines the next generation sequencing technolo-gies, therapeutic target analyses and drug response monitoring using patient derived xenografts (PDX). This strategy was validated using ovarian tumors as an example. The mate-pair next generation sequencing (MPseq) protocol was used to identify structural alterations and followed by analysis of potentially targetable alterations. Human tumors grown in immunocompromised mice were treated with drugs selected based on the genomic analyses. Results demonstrated a good correlation between the predicted and the observed responses in the PDX model. The presented approach can be used to test the efficacy of combination treatments and aid personalized treatment for patients with recurrent cancer, specifically in cases when standard therapy fails and there is a need to use drugs off label.

Here we present a protocol to test the efficacy of targeted therapies selected based on the genomic makeup of a tumor. The protocol describes identification and validation of structural DNA rearrangements, engraftment of patients&#8217; tumors into mice and testing responses to corresponding drugs.

We present here an integrative approach for testing efficacy of targeted therapies that combines the next generation sequencing technolo-gies, therapeutic ...

Measuring Real-time Drug Response in Organotypic Tumor Tissue Slices

Tumor tissues are composed of cancerous cells, infiltrated immune cells, endothelial cells, fibroblasts, and extracellular matrix. This complex milieu constitutes the tumor microenvironment (TME) and can modulate response to therapy in vivo or drug response ex vivo. Conventional cancer drug discovery screens are carried out on cells cultured in a monolayer, a system critically lacking the influence of TME. Thus, experimental systems that integrate sensitive and high-throughput assays with physiological TME will strengthen the preclinical drug discovery process. Here, we introduce ex vivo tumor tissue slice culture as a platform for medium-high-throughput drug screening. Organotypic tissue slice culture constitutes precisely-cut, thin tumor sections that are maintained with the support of a porous membrane in a liquid-air interface. In this protocol, we describe the preparation and maintenance of tissue slices prepared from mouse tumors and tumors from patient-derived xenograft (PDX) models. To assess changes in tissue viability in response to drug treatment, we leveraged a biocompatible luminescence-based viability assay that enables real-time, rapid, and sensitive measurement of viable cells in the tissue. Using this platform, we evaluated dose-dependent responses of tissue slices to the multi-kinase inhibitor, staurosporine, and cytotoxic agent, doxorubicin. Further, we demonstrate the application of tissue slices for ex vivo pharmacology by screening 17 clinical and preclinical drugs on tissue slices prepared from a single PDX tumor. Our physiologically-relevant, highly-sensitive, and robust ex vivo screening platform will greatly strengthen preclinical oncology drug discovery and treatment decision making.&#160;

We introduce a protocol for measuring real-time drug response in organotypic tumor tissue slices. The experimental strategy outlined here provides a platform to carry out medium-high throughput drug screens on tissue slices derived from clinical or mouse tumors in ex vivo conditions.

Tumor tissues are composed of cancerous cells, infiltrated immune cells, endothelial cells, fibroblasts, and extracellular matrix. This complex milieu ...

Orthotopic Transplantation of Breast Tumors as Preclinical Models for Breast Cancer

Preclinical models that faithfully recapitulate tumor heterogeneity and therapeutic response are critical for translational breast cancer research. Immortalized cell lines are easy to grow and genetically modify to study molecular mechanisms, yet the selective pressure from cell culture often leads to genetic and epigenetic alterations over time. Patient-derived xenograft (PDX) models faithfully recapitulate the heterogeneity and drug response of human breast tumors. PDX models exhibit a relatively short latency after orthotopic transplantation that facilitates the investigation of breast tumor biology and drug response. The transplantable genetically engineered mouse models allow the study of breast tumor immunity. The current protocol describes the method to orthotopically transplant breast tumor fragments into the mammary fat pad followed by drug treatments. These preclinical models provide valuable approaches to investigate breast tumor biology, drug response, biomarker discovery and mechanisms of drug resistance.

Patient-derived xenograft (PDX) models and transplantable genetically engineered mouse models faithfully recapitulate human disease and are preferred models for basic and translational breast cancer research. Here, a method is described to orthotopically transplant breast tumor fragments into the mammary fat pad to study tumor biology and evaluate drug response.

Preclinical models that faithfully recapitulate tumor heterogeneity and therapeutic response are critical for translational breast cancer research. ...

Creating Matched In vivo/In vitro Patient-Derived Model Pairs of PDX and PDX-Derived Organoids for Cancer Pharmacology Research

Patient-derived tumor xenografts (PDXs) are considered the most predictive preclinical models, largely believed to be driven by cancer stem cells (CSC) for conventional cancer drug evaluation. A large library of PDXs is reflective of the diversity of patient populations and thus enables population based preclinical trials (&#8220;Phase II-like mouse clinical trials&#8221;); however, PDX have practical limitations of low throughput, high costs and long duration. Tumor organoids, also being patient-derived CSC-driven models, can be considered as the in vitro equivalent of PDX, overcoming certain PDX limitations for dealing with large libraries of organoids or compounds. This study describes a method to create PDX-derived organoids (PDXO), thus resulting in paired models for in vitro and in vivo pharmacology research. Subcutaneously-transplanted PDX-CR2110 tumors were collected from tumor-bearing mice when the tumors reached 200-800 mm3, per an approved autopsy procedure, followed by removal of the adjacent non-tumor tissues and dissociation into small tumor fragments. The small tumor fragments were washed and passed through a 100 &#181;m cell strainer to remove the debris. Cell clusters were collected and suspended in basement membrane extract (BME) solution and plated in a 6-well plate as a solid droplet with surrounding liquid media for growth in a CO2 incubator. Organoid growth was monitored twice weekly under light microscopy and recorded by photography, followed by liquid medium change 2 or 3 times a week. The grown organoids were further passaged (7 days later) at a 1:2 ratio by disrupting the BME embedded organoids using mechanical shearing, aided by addition of trypsin and the addition of 10 &#181;M Y-27632. Organoids were cryopreserved in cryo-tubes for long-term storage, after release from BME by centrifugation, and also sampled (e.g., DNA, RNA and FFPE block) for further characterization.

A method is described to create organoids using patient-derived xenografts (PDX) for in vitro screening, resulting in matched pairs of in vivo/in vitro models. PDX tumors were harvested/processed into small pieces mechanically or enzymatically, followed by the Clevers&#8217; method to grow tumor organoids that were passaged, cryopreserved and characterized against the original PDX.

Patient-derived tumor xenografts (PDXs) are considered the most predictive preclinical models, largely believed to be driven by cancer stem cells (CSC) ...

High-Throughput In Vitro Assay using Patient-Derived Tumor Organoids

Patient-derived tumor organoids (PDOs) are expected to be a preclinical cancer model with better reproducibility of disease than traditional cell culture models. PDOs have been successfully generated from a variety of human tumors to recapitulate the architecture and function of tumor tissue accurately and efficiently. However, PDOs are unsuitable for an in vitro high-throughput assay system (HTS) or cell analysis using 96-well or 384-well plates when evaluating anticancer drugs because they are heterogeneous in size and form large clusters in culture. These cultures and assays use extracellular matrices, such as Matrigel, to create tumor tissue scaffolds. Therefore, PDOs have a low throughput and high cost, and it has been difficult to develop a suitable assay system. To address this issue, a simpler and more accurate HTS was established using PDOs to evaluate the potency of anticancer drugs and immunotherapy. An in vitro HTS was created that uses PDOs established from solid tumors cultured in 384-well plates. An HTS was also developed for assessment of antibody-dependent cellular cytotoxicity activity to represent the immune response using PDOs cultured in 96-well plates.

High-Throughput In Vitro Assay using Patient-Derived Tumor Organoids

A highly accurate in vitro high-throughput assay system was developed to evaluate anticancer drugs using patient-derived tumor organoids (PDOs), similar to cancer tissues but are unsuitable for in vitro high-throughput assay systems with 96-well and 384-well plates.

Patient-derived tumor organoids (PDOs) are expected to be a preclinical cancer model with better reproducibility of disease than traditional cell culture ...

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Novel 3D cancer organoid cultures derived from clinical patient specimens represent an important model system to evaluate intratumor heterogeneity and treatment response to targeted inhibitors in cancer. Pioneering work in gastrointestinal and pancreatic cancers has highlighted the promise of patient-derived organoids (PDOs) as a patient-proximate culture system, with an increasing number of models emerging. Similarly, work in other cancer types has focused on establishing organoid models and optimizing culture protocols. Notably, 3D cancer organoid models maintain the genetic complexity of original tumor specimens and thus translate tumor-derived sequencing data into treatment with genetically informed targeted therapies in an experimental setting. Further, PDOs might foster the evaluation of rational combination treatments to overcome resistance-associated adaptation of tumors in the future. The latter focuses on intense research efforts in non-small-cell lung cancer (NSCLC), as resistance development ultimately limits the treatment success of targeted inhibitors. An early assessment of therapeutically targetable mechanisms using NSCLC PDOs could help inform rational combination treatments. This manuscript describes a standardized protocol for the cell culture plate-based assessment of drug sensitivities to targeted inhibitors in NSCLC-derived 3D PDOs, with potential adaptability to combinational treatments and other treatment modalities.

This protocol describes a standardized evaluation of drug sensitivities to targeted signaling inhibitors in NSCLC patient-derived organoid models.

Novel 3D cancer organoid cultures derived from clinical patient specimens represent an important model system to evaluate intratumor heterogeneity and ...

Establishment of Zebrafish Patient-Derived Xenografts from Pancreatic Cancer for Chemosensitivity Testing

Cancer is one of the main causes of death worldwide, and the incidence of many types of cancer continues to increase. Much progress has been made in terms of screening, prevention, and treatment; however, preclinical models that predict the chemosensitivity profile of cancer patients are still lacking. To fill this gap, an in vivo patient-derived xenograft model was developed and validated. The model was based on zebrafish (Danio rerio) embryos at 2 days post fertilization, which were used as recipients of xenograft fragments of tumor tissue taken from a patient's surgical specimen. 
It is also worth noting that bioptic samples were not digested or disaggregated, in order to maintain the tumor microenvironment, which is crucial in terms of analyzing tumor behavior and the response to therapy. The protocol details a method for establishing zebrafish-based patient-derived xenografts (zPDXs) from primary solid tumor surgical resection. After screening by an anatomopathologist, the specimen is dissected using a scalpel blade. Necrotic tissue, vessels, or fatty tissue are removed and then chopped into 0.3 mm x 0.3 mm x 0.3 mm pieces. 
The pieces are then fluorescently labeled and xenotransplanted into the perivitelline space of zebrafish embryos. A large number of embryos can be processed at a low cost, enabling high-throughput in vivo analyses of the chemosensitivity of zPDXs to multiple anticancer drugs. Confocal images are routinely acquired to detect and quantify the apoptotic levels induced by chemotherapy treatment compared to the control group. The xenograft procedure has a significant time advantage, since it can be completed in a single day, providing a reasonable time window to carry out a therapeutic screening for co-clinical trials.

Preclinical models aim to advance the knowledge of cancer biology and predict treatment efficacy. This paper describes the generation of zebrafish-based patient-derived xenografts (zPDXs) with tumor tissue fragments. The zPDXs were treated with chemotherapy, the therapeutic effect of which was assessed in terms of cell apoptosis of the transplanted tissue.

Cancer is one of the main causes of death worldwide, and the incidence of many types of cancer continues to increase. Much progress has been made in terms ...

Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients

Summary

Explore More Videos

Chapters in this video

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies

Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel

Method for Novel Anti-Cancer Drug Development using Tumor Explants of Surgical Specimens

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Measuring Real-time Drug Response in Organotypic Tumor Tissue Slices

Orthotopic Transplantation of Breast Tumors as Preclinical Models for Breast Cancer

Creating Matched In vivo/In vitro Patient-Derived Model Pairs of PDX and PDX-Derived Organoids for Cancer Pharmacology Research

High-Throughput In Vitro Assay using Patient-Derived Tumor Organoids

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Establishment of Zebrafish Patient-Derived Xenografts from Pancreatic Cancer for Chemosensitivity Testing